Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 14/20 | 0.42 |
| ▸ | HTR6 | P50406 | 13/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812783 | 0.82 | HRH1 (0.63) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL952820 | 0.79 | HRH1 (0.51) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL955476 | 0.79 | HRH1 (0.44) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL952397 | 0.77 | HRH1 (0.43) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL957310 | 0.77 | HRH1 (0.51) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL2813851 | 0.77 | HRH1 (0.61) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL2809846 | 0.75 | MCHR1 (0.51) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL2814502 | 0.74 | HRH1 (0.50) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL2810407 | 0.73 | PTGDR2 (0.51) | — | |
| SCHEMBL2810402 | 0.73 | HRH1 (0.58) | HRH1HTR6ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | claimed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | claimed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | claimed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HRH1 457/4885HTR6 21/4885ADRA2A 138/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HRH1 457/4885HTR6 21/4885ADRA2A 138/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HRH1 457/4885HTR6 21/4885ADRA2A 138/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HRH1 457/4885HTR6 21/4885ADRA2A 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.